Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®)

被引：0
|
作者：
Marye J. Boers-Sonderen
Carla M. L. van Herpen
Winette T. A. van der Graaf
Ingrid M. E. Desar
Mirjam G. W. Arens- van der Logt
Yvo M. de Beer
Petronella B. Ottevanger
Nielka P. van Erp
机构：
[1] Radboud University Medical Centre,Department of Medical Oncology, 452
[2] Maastricht University Medical Centre+,Department of Clinical Pharmacy and Toxicology
[3] Maastricht University,School CAPHRI
[4] Maastricht University,Department of Toxicology
[5] Radboud University Medical Centre,Department of Clinical Pharmacy
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词：
Pegylated liposomal doxorubicin; Pharmacokinetics; Pharmacodynamics; Progression-free survival; Toxicities;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：457 / 463
页数：6
相关论文
共 50 条
  • [1] Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (CaelyxA®)
    Boers-Sonderen, Marye J.
    van Herpen, Carla M. L.
    van der Graaf, Winette T. A.
    Desar, Ingrid M. E.
    Arens-van der Logt, Mirjam G. W.
    de Beer, Yvo M.
    Ottevanger, Petronella B.
    van Erp, Nielka P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (03) : 457 - 463
  • [2] Evaluating the effects of bortezomib (Velcade®) on the pharmacokinetics (PK) of pegylated liposomal doxorubicin (Doxil®, PLD)
    La-Beck, Ninh M.
    Walko, Christine M.
    Scoggins, Lakia
    Dees, E. Claire
    Orlowski, Robert Z.
    Wu, Huali
    Amantea, Michael
    Fardin, Mahsa
    Zamboni, William
    CANCER RESEARCH, 2012, 72
  • [3] Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer
    Rom, Joachim
    Bechstein, Sarah
    Domschke, Christoph
    Golatta, Michael
    Mayer, Christine
    Heil, Joerg
    Thum, Janina
    Smetanay, Katharina
    Windemuth-Kieselbach, Christine
    Wallwiener, Markus
    Marme, Frederik
    Schuetz, Florian
    Sohn, Christof
    Schneeweiss, Andreas
    ANTI-CANCER DRUGS, 2014, 25 (02) : 219 - 224
  • [4] Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel
    Evangelos Briasoulis
    Vasilis Karavasilis
    Eleftheria Tzamakou
    Dimitra Rammou
    Kali Soulti
    Christina Piperidou
    Nicholas Pavlidis
    Cancer Chemotherapy and Pharmacology, 2004, 53 : 452 - 457
  • [5] Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel
    Briasoulis, E
    Karavasilis, V
    Tzamakou, E
    Rammou, D
    Soulti, K
    Piperidou, C
    Pavlidis, N
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (05) : 452 - 457
  • [6] Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
    Lyass, O
    Uziely, B
    Ben-Yosef, R
    Tzemach, D
    Heshing, NI
    Lotem, M
    Brufman, G
    Gabizon, A
    CANCER, 2000, 89 (05) : 1037 - 1047
  • [7] The impact of five different administration intervals on the pharmacokinetics (PK) of paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) combination
    Cattel, Luigi
    Milla, Paola
    Cerutti, Eleonora
    Pedani, Fulvia
    Airoldi, Mario
    Crova, Alice
    ANNALS OF ONCOLOGY, 2007, 18 : 82 - 83
  • [8] An open-label study to evaluate dose and cycle dependence of the pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD).
    Gabizon, A.
    Isacson, R.
    Rosengarten, O.
    Tzemach, D.
    Shmeeda, H.
    Sapir, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 82S - 82S
  • [9] Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo
    Yuan, Y.
    Orlow, S. J.
    Curtin, J.
    Downey, A.
    Muggia, F.
    ECANCERMEDICALSCIENCE, 2008, 2
  • [10] Pegylated liposomal doxorubicin (Caelyx™) in recurrent ovarian cancer
    Stebbing, J
    Gaya, A
    CANCER TREATMENT REVIEWS, 2002, 28 (02) : 121 - 125
12345